Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Deal Details

C/PIndustryStatusTicker(s)Issuer(s)Size(m)TranchesRegionDate
HYC
HLTH
PRCD
LIMACO
Limacorporate SpA€295
1EMEA
Jan 20, 2023
currency
EUR
size (m)
295.000
maturity
Feb 1, 2038
type
Floating
tenor
5.000
call
1
registration
144A/Reg S
benchmark
-
ranking
Sr. Secured
moody's
B3
s&p
B-
fitch
-
size description
-
re-open/tap
No
ipt
E+575-600bp coupon at 92-93 OID
ipt-pxd
-
guidance
E+575bp coupon at 92-93 OID
spread
575
coupon
-
spread set
-
price
93.00000
yield
-
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
left lead
active leads
joint leads
passive leads
-
co-managers
-
coordinating managers
-
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
left lead
active leads
joint leads
passive leads
-
co-managers
-
coordinating managers
-
Tranche Comments
Registration: 144A/Reg S;
Deal Comments
01/20/2023 LimaCorporate SpA (LIMACO) EUR295m 144A/Reg S sr sec FRN due 02/0128 (5y). NC1 (MWC B+50bp), then 101, 100. Equity claw: 1y 40% at par + then applicable coupon. B3/B- (negative, stable expected post transaction/stable). Via CS/GS (B&D) jt glocos/IMI/Mizuho/UniCredit jt books. No reg rights. List Lux. NY law. Settles 02/03 (T+10). IPT: E+575-600bp coupon at 92-93 OID. Px talk: E+575bp coupon at 92-93 OID. Priced: 3mE+575bp at 93.00. Small group meetings started 01/17 (Investor call at 2:30pm UKT 01/17). Books closed at 11am UKT 01/20. UOP: along with EUR12.5m draw on a new EUR65m revolver, EUR7m cash on hand and EUR45.2m equity contribution, to repay and cancel existing EUR60m revolver (EUR54m drawn), redeem its EUR275 sr sec notes due 08/15/23 (callable at 100). Equity sponsor: EQT. Biz: manufacturer and provider of orthopedic implants and enabling technologies for extremities, knee and hip joint replacements. HQ: Udine, Italy.

Commentary

Explore all other Commentary & Deal Flow

Deal Flow

Explore all other Commentary & Deal Flow
We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.